海翔药业新增创新药概念，股价连续异动，2025年预亏收窄

Core Viewpoint - Haishang Pharmaceutical (002099) has introduced the "innovative drug" concept based on its R&D strategy and past performance, while also announcing abnormal stock trading fluctuations due to significant price changes over three consecutive trading days [1] Stock Performance - The stock price has shown significant volatility in the past week, with a closing price of 7.51 yuan on February 6, reaching a peak of 8.26 yuan on February 9, and closing at 8.38 yuan on February 10, resulting in a cumulative increase of 23.13% over five days and 34.78% year-to-date [2] - As of February 12, the latest price was 8.41 yuan, with a daily fluctuation of 6.71% and a turnover rate of 5.09%, indicating a net outflow of 48.41 million yuan from major funds on that day [2] - The top five buyers on February 10 were primarily from the Shenzhen Stock Connect and institutional investors, reflecting increased capital attention [2] Financial Report Analysis - The company expects a net loss attributable to shareholders of 90 million to 135 million yuan for 2025, marking a narrowing of losses compared to 2024, but continuing a three-year trend of losses primarily due to pressure on the pharmaceutical segment and a decline in the dye business [3] - Revenue for the first three quarters of 2025 is projected at 1.367 billion yuan, a year-on-year decrease of 5.39%, although there is a quarter-on-quarter improvement [3] - Some institutions predict a potential turnaround in net profit to 367 million yuan for 2025, but caution is advised based on a minority of institutional views [3] Institutional Perspectives - Market sentiment is generally neutral, with low frequency of institutional research and no significant changes in ratings [4] - The recent price surge in dyes may enhance profit elasticity, but the company still faces dual business pressures, and investments in innovative drugs carry high risks [4]